Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis

NCT07388992 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Observational
Started
2026-03-16
Last updated
2026-03-23

Condition(s) studied

Multiple SclerosisHealthy Adult

Study summary

The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: For people living with multiple sclerosis (pwMS): 1. Age at inclusion between =18 and =65 years old 2. Signed informed consent and ability to comply with study and follow-up. 3. Confirmed MS diagnosis according to McDonald criteria (2017) 4. Expanded Disability Status Scale EDSS = 6 5. Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies) 6. Ability and willingness to participate in and comply with all study procedures defined in the protocol 7. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category For Healthy volunteers : 1. Age at inclusion between =18 and =65 years old 2. Signed informed consent and ability to comply with study and follow-up. 3. Ability and willingness to participate in and comply with all study procedures defined in the protocol 4. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category Exclusion Criteria: For pwMS: 1. Participants with a relapse within the past 3 months before the inclusion 2. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator 3. Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator 4. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent. For healthy volunteers (HV): 1. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator 2. Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator 3. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.

Primary outcome measure(s)

  • description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities — enrollment
    Measurement of daily life-like activity movements by Optical Motion Capture, pressure sensitive walkway and wearable sensors

Trial sites (1)

FacilityCityRegionStatus
CHU Lille Lille France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388992 on ClinicalTrials.gov ↗ ← All trials in France